Explore our Deck
Find the company overview and discover with us exciting scientific developments and business opportunities.
Latest News
SEC Filings
8K + XBRL Form 4
September 27, 2024
Richard Prins FORM 144
August 12, 2024
Richard Prins FORM 4
August 12, 2024
IGC Pharma Form 10-Q Quarter Ended June 30, 2024
August 7, 2024
From the CEO's desk:
Vertical integration
Periodic updates and perspectives on various aspects of our business.
Our Research
IGC-AD1
Is designed to target neuroinflammation, potentially stabilize CB1r function and address neurotransmitter imbalances, all hallmarks associated with agitation in Alzheimer Dementia
TGR-63
A small molecule designed to break down plaque formation in the brain, exhibiting outstanding biocompatibility, the ability to breach the blood–brain barrier, and pre-clinical behavioral efficacy.
A.I.
To mine the depths of decades-worth of Alzheimer’s research, bringing to light novel insights and pioneering advanced treatments faster than ever for a healthier elderliness.
Locations
Our company has operations in different countries
manufacturing vertical and R&D capabilities.